Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients
- PMID: 21333025
- PMCID: PMC3048471
- DOI: 10.1186/1748-717X-6-19
Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients
Abstract
Background: Sensorineural hearing loss (SNHL) is one of the major long term side effects from radiation therapy (RT) in nasopharyngeal cancer (NPC) patients. This study aims to review the incidences of SNHL when treating with different radiation techniques. The additional objective is to determine the relationship of the SNHL with the radiation doses delivered to the inner ear.
Methods: A retrospective cohort study of 134 individual ears from 68 NPC patients, treated with conventional RT and IMRT in combination with chemotherapy from 2004-2008 was performed. Dosimetric data of the cochlea were analyzed. Significant SNHL was defined as >15 dB increase in bone conduction threshold at 4 kHz and PTA (pure tone average of 0.5, 1, 2 kHz). Relative risk (RR) was used to determine the associated factors with the hearing threshold changes at 4 kHz and PTA.
Results: Median audiological follow up time was 14 months. The incidence of high frequency (4 kHz) SNHL was 44% for the whole group (48.75% in the conventional RT, 37% with IMRT). Internal auditory canal mean dose of >50 Gy had shown a trend to increase the risk of high frequency SNHL (RR 2.02 with 95% CI 1.01-4.03, p=0.047).
Conclusion: IMRT and radiation dose limitation to the inner ear appeared to decrease SNHL.
Figures
Similar articles
-
Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1335-42. doi: 10.1016/j.ijrobp.2008.07.034. Epub 2008 Oct 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 18922648
-
Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma.Acta Otolaryngol. 2019 Mar;139(3):263-268. doi: 10.1080/00016489.2019.1566778. Epub 2019 Mar 14. Acta Otolaryngol. 2019. PMID: 30870056
-
Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.Cancer. 2006 Feb 15;106(4):820-9. doi: 10.1002/cncr.21683. Cancer. 2006. PMID: 16421885
-
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15. Laryngoscope. 2007. PMID: 17202923 Review.
-
Radiotherapy-induced ear toxicity.Cancer Treat Rev. 2003 Oct;29(5):417-30. doi: 10.1016/s0305-7372(03)00066-5. Cancer Treat Rev. 2003. PMID: 12972360 Review.
Cited by
-
Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.Chin J Cancer. 2015 May 20;34(5):189-97. doi: 10.1186/s40880-015-0016-8. Chin J Cancer. 2015. PMID: 26058563 Free PMC article.
-
Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers.Indian J Palliat Care. 2015 May-Aug;21(2):164-7. doi: 10.4103/0973-1075.156479. Indian J Palliat Care. 2015. PMID: 26009669 Free PMC article.
-
Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region.Turk Arch Otorhinolaryngol. 2022 Dec;60(4):212-219. doi: 10.4274/tao.2022.2022-6-2. Epub 2023 Jul 7. Turk Arch Otorhinolaryngol. 2022. PMID: 37456600 Free PMC article.
-
A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.Strahlenther Onkol. 2018 May;194(5):375-385. doi: 10.1007/s00066-017-1251-5. Epub 2018 Jan 4. Strahlenther Onkol. 2018. PMID: 29302704 Clinical Trial. English.
-
Complementary acupuncture treatment and reduced risk of sudden sensorineural hearing loss in nasopharyngeal carcinoma patients: a retrospective, nested case-control study.J Cancer Surviv. 2025 Aug;19(4):1285-1292. doi: 10.1007/s11764-024-01552-z. Epub 2024 Jun 4. J Cancer Surviv. 2025. PMID: 38833080
References
-
- Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE. et al.Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317. - PubMed
-
- Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW. et al.Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23(27):6730–6738. doi: 10.1200/JCO.2005.16.790. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous